Karyopharm Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Karyopharm Therapeutics

01/05/2023 19:31

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 3 (estimated). 
    * The Newton Center Massachusetts-based  company is expected
to
report  a 23.2% decrease in revenue to $36.605 million from
$47.67 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Karyopharm
Therapeutics
Inc is for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $8​, above​ its last closing price of $3.58.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.35       -0.35      -0.43     Missed  -21.8
 Sep. 30 2022  -0.58       -0.57      -0.45     Beat    20.4
 Jun. 30 2022  -0.63       -0.63      -0.62     Beat    2.1​
 Mar. 31 2022  -0.62       -0.63      -0.53     Beat    16
 ​​Dec.        -0.35       -0.52      0.46      Beat    189.2
 31 2021                                                
 Sep. 30 2021  -0.69       -0.67      -0.69     Missed  -2.5​
 Jun. 30 2021  -0.75       -0.75      -0.71     Beat    5.2
 Mar. 31 2021  -0.73       -0.71      -0.77     Missed  -8.3
 This summary was machine generated May 1 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated